Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immunocore Holdings plcNASDAQ: IMCR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $61.11M rose 8.2% year over year, behind the +17.2% change in trailing-twelve-month research & development. Sequentially, it rose 4.6% from the prior quarter. Over 3 fiscal years it compounded at +34.4% a year.
Context
- Research & development amounted to 68.7% of revenue in FY2025, down 2.8 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.2% toward the trailing-twelve-month pace of +17.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
Mixed currencies · from the income statement
- Latest · FY2025
- 204.47M USD
- Year-over-year change
- +15.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 204.47M | +15.2% |
| FY2024 | 2024-12-31 | 177.44M | — |
| FY2023 | 2023-12-31 | 129.42M | +53.5% |
| FY2022 | 2022-12-31 | 84.31M | +13.5% |
| FY2021 | 2021-12-31 | 74.31M | — |
Research & Development vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.2% is the 5th highest of 11, against a peer median of +7.0%.
- Research & development amounts to 67.2% of revenue for IMCR, versus a peer median of 334.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €2.18B EUR | -0.6% | +9.6% | 82.6% | |
| LTM Jun 2026 | $497M USD | +2.5% | +22.0% | 424.8% | |
| LTM Mar 2026 | $259.11M USD | +17.2% | +34.4% | 67.2% | |
| LTM Jun 2026 | $255.77M USD | +11.4% | +6.3% | 243.6% | |
| LTM Sep 2026 | $252.23M USD | +33.2% | -5.7% | 138.2% | |
| LTM Mar 2026 | €201.11M EUR | +27.4% | +19.9% | 539.2% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $127.65M USD | +60.8% | +33.1% | 590.6% | |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $23.92M USD | -1.0% | -9.4% | 32.9% | |
| Peer median (excluding IMCR) | — | +7.0% | +7.9% | 334.2% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.